Shuttle Pharmaceuticals Holdings, Inc. Files 2023 Annual Report

TL;DR

<b>Shuttle Pharmaceuticals Holdings, Inc. has filed its annual 10-K report for the fiscal year ended December 31, 2023, detailing its financial performance and business operations.</b>

AI Summary

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) filed a Annual Report (10-K) with the SEC on March 21, 2024. Shuttle Pharmaceuticals Holdings, Inc. filed its 10-K report for the fiscal year ending December 31, 2023. The company is incorporated in Delaware and operates in the Pharmaceutical Preparations industry (SIC 2834). Its principal business address is located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879. The filing includes financial data for the fiscal years 2023 and 2022. The report was filed on March 21, 2024.

Why It Matters

For investors and stakeholders tracking Shuttle Pharmaceuticals Holdings, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Shuttle Pharmaceuticals' financial health and operational status for the fiscal year 2023, which is crucial for investors to assess the company's performance and future prospects. The detailed financial information, including balance sheets and income statements for 2023 and 2022, allows for year-over-year comparison and trend analysis, aiding in investment decisions.

Risk Assessment

Risk Level: low — Shuttle Pharmaceuticals Holdings, Inc. shows low risk based on this filing. The filing is a standard 10-K annual report, which typically contains routine financial and operational disclosures without immediate significant market-moving events.

Analyst Insight

Investors should review the detailed financial statements and risk factors within the 10-K to understand Shuttle Pharmaceuticals' financial position and strategic direction.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 2024-03-21 — Filing Date (Date the 10-K was filed)
• 2023 — Reporting Year (Primary year for financial data)
• 2022 — Prior Year (Comparative year for financial data)

Key Players & Entities

• Shuttle Pharmaceuticals Holdings, Inc. (company) — Filer name
• 2023-12-31 (date) — Fiscal year end
• 2024-03-21 (date) — Filing date
• Gaithersburg, MD (location) — Business address city and state
• 20879 (location) — Business address zip code
• 2834 (industry) — Standard Industrial Classification for Pharmaceutical Preparations

FAQ

Industry Context

Shuttle Pharmaceuticals Holdings, Inc. operates within the Pharmaceutical Preparations industry, which is characterized by research, development, and manufacturing of drugs and medicines.

Regulatory Implications

As a pharmaceutical company, Shuttle Pharmaceuticals is subject to regulations from bodies like the FDA, governing drug development, testing, and approval processes.

What Investors Should Do

1. Review the full 10-K filing for detailed financial statements and management's discussion and analysis.
2. Analyze the company's business description and risk factors to understand its operational landscape.
3. Compare the 2023 financial data with 2022 data to identify trends and performance changes.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K filing.
• 2024-03-21: 10-K Filing Date — Date Shuttle Pharmaceuticals Holdings, Inc. submitted its annual report.

Year-Over-Year Comparison

This filing represents the annual 10-K report for the fiscal year 2023, providing a comprehensive update compared to previous filings.

Key Financial Figures

• $0.00001 — he registrant's common stock, par value $0.00001 per share, held by non-affiliates of th

Filing Documents

• form10-k.htm (10-K) — 1843KB
• ex21.htm (EX-21) — 2KB
• ex23-1.htm (EX-23.1) — 3KB
• ex23-2.htm (EX-23.2) — 4KB
• ex31-1.htm (EX-31.1) — 11KB
• ex31-2.htm (EX-31.2) — 12KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• form10-k_001.jpg (GRAPHIC) — 26KB
• form10-k_002.jpg (GRAPHIC) — 104KB
• form10-k_003.jpg (GRAPHIC) — 20KB
• form10-k_004.jpg (GRAPHIC) — 20KB
• form10-k_005.jpg (GRAPHIC) — 152KB
• ex23-2_001.jpg (GRAPHIC) — 2KB
• 0001493152-24-010822.txt (&nbsp;) — 7656KB
• shph-20231231.xsd (EX-101.SCH) — 49KB
• shph-20231231_cal.xml (EX-101.CAL) — 66KB
• shph-20231231_def.xml (EX-101.DEF) — 231KB
• shph-20231231_lab.xml (EX-101.LAB) — 432KB
• shph-20231231_pre.xml (EX-101.PRE) — 329KB
• form10-k_htm.xml (XML) — 772KB

Business

Business 4 Item 1A.

Risk Factors

Risk Factors 24 Item 1B. Unresolved Staff Comments 52 Item 1C. Cybersecurity 52 Item 2.

Properties

Properties 53 Item 3.

Legal Proceedings

Legal Proceedings 53 Item 4. Mine Safety Disclosures 53 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 54 Item 6. [Reserved] 55 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 55 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 60 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 61 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 62 Item 9A.

Controls and Procedures

Controls and Procedures 62 Item 9B. Other Information 62 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 62 PART III Item 10. Directors, Executive Officers and Corporate Governance 63 Item 11.

Executive Compensation

Executive Compensation 72 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 75 Item 13. Certain Relationships and Related Transactions, and Director Independence 76 Item 14. Principal Accountant Fees and Services 77 PART IV Item 15. Exhibit and Financial Statement Schedules 78 Item 16. Form 10–K Summary 80

SIGNATURES

SIGNATURES 81 2 FORWARD LOOKING STATEMENTS This Annual Report on Form 10-K (including the section regarding Management's Discussion and Analysis and Results of Operations, the "Annual Report") contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements are based on our management's beliefs and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. All statements other than statements of historical facts contained in this Form 10-K are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "project," "continue," "potential," "ongoing" or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and INDs, NDAs other regulatory submissions; our expected dependence on third party collaborators for developing, obtaining regulatory approval for and commercializing product candidates; our receipt and timing of any milestone payments or royalties under any research collaboration a

View Full Filing

View this 10-K filing on SEC EDGAR